• DOI:10.1136/ANNRHEUMDIS-2014-EULAR.1545
Corpus ID: 76139929

AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®

@article{Kronthaler2014AB0412PP,
  title={AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®},
  author={U. Kronthaler and M. Baron and J. Poetzl and A. da Silva},
  journal={Annals of the Rheumatic Diseases},
  year={2014},
  volume={73},
  pages={943 - 943}
}

U. Kronthaler, M. Baron, +1 author A. da Silva

Published 2014

Medicine

Annals of the Rheumatic Diseases

Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis. Biosimilars are approved biologics with comparable quality, safety and efficacy to a reference product, which has lost exclusivity, aiming to offer more affordable treatment to patients. Objectives Here we present results on the pre-clinical in-vivo characterization of the proposed adalimumab biosimilar GP2017 in terms of pharmacokinetics as well as safety. Methods… CONTINUE READING

View on BMJ

Save to Library

Create Alert

Cite

Launch Research Feed